
|Articles|March 1, 2020
- Pharmaceutical Executive-03-01-2020
- Volume 40
- Issue 3
Pharmaceutical Executive, March 2020 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 6 years ago
The Multichannel Reach: Balancing the Local and Global Voiceover 6 years ago
Market Access: From Being to Becomingover 6 years ago
Consider Data Before It’s a Problemover 6 years ago
Multichannel Marketing: Integrating Omnichannelover 6 years ago
Feds Target Biosimilar Anticompetitive Practicesover 6 years ago
Blood Feud Divides Europe Over Plasma Shortfallsover 6 years ago
Social Media’s Influence in Messaging Mixover 6 years ago
Habib Bennaceur: Following the Scienceover 6 years ago
A Bad Deal with Data?over 6 years ago
Country Report: United Arab EmiratesAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Significance of FDA’s First Warning Letter for Inappropriate Use of AI
2
Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion
3
Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance
4
M&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo
5




